Zacks: Enzymotec Ltd. (ENZY) Receives Consensus Rating of “Hold” from Brokerages
Shares of Enzymotec Ltd. (NASDAQ:ENZY) have received an average broker rating score of 3.33 (Hold) from the three analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a sell recommendation and two have assigned a hold recommendation to the company.
Brokers have set a 1 year consensus price target of $10.30 for the company and are expecting that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also given Enzymotec an industry rank of 179 out of 265 based on the ratings given to related companies.
Several analysts have commented on ENZY shares. Wells Fargo & Company lifted their target price on shares of Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research note on Monday, October 30th. Jefferies Group LLC restated a “hold” rating and set a $11.50 target price on shares of Enzymotec in a report on Thursday, October 19th. Zacks Investment Research upgraded shares of Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a report on Saturday, August 12th.
Shares of Enzymotec (NASDAQ:ENZY) traded up $0.03 during trading hours on Monday, reaching $11.85. 8,800 shares of the company were exchanged, compared to its average volume of 64,160. Enzymotec has a 1 year low of $5.40 and a 1 year high of $12.35.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.